3Shibata T, Takeuchi S, Yokota S, et al. Effects of peroxisome prolirferator-activated receptor -α and -γ agonist, JTT-501, on diabetic complicatikns in zucker diabrtic fatty rats [J]. Br J Pharmacol, 2000,130:495-504.
4Shinkai H, Onogi S, Tanaka M, et al. Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents [J]. J Med Chem, 1998,41(11):1927-1933.
5Hindley RM. Novel compounds [P]. US Pat: 5002953, 1991-03-26.
6Takatsuki AK, Asaka MS. Process for producing isoxazolidinedione compound [P]. US Pat: 6248897, 2001-06-19.
7Berger J, Leibowitz MD, Doebber TW, et al. Novel peroxisome proliferator-activated receptor (PPARγ) and PPARδ ligands produce distinct biological effects [J]. J Biol Chem, 1999,274(10):6718-6725.
9Dey D,Anumula M,Pandey B,et al.Mechanism of action studies with novel thiazolidinedione BLX-1002 with no PPARγ affinity[J].Diabetologia,2005,48(S1):A44.
10Fagerberg B,Edwards S,Halmos T,et al.Improvement in postprandial lipid handing and glucose tolerance with tesaglitazar in insulin-resistant,nondiabetic patients[J].Diabetologia,2005,48(S1):A274.
